No­vo Hold­ings in­vests in Hemab, a com­pa­ny go­ing against the he­mo­phil­ia gene ther­a­py grain with a plan for bis­pecifics

No­vo Hold­ings, the hold­ing com­pa­ny com­pris­ing No­vo Nordisk and man­ag­ing the No­vo Nordisk Foun­da­tion’s as­sets, has made a new in­vest­ment through its seed cap­i­tal arm.

The in­cu­ba­tor No­vo Seeds is fund­ing a com­pa­ny called Hemab ApS, which is fo­cused on de­vel­op­ing bis­pe­cif­ic an­ti­bod­ies for rare bleed­ing dis­or­ders. Co-found­ed by two for­mer No­vo Nordisk ex­ecs in their he­mo­phil­ia R&D de­part­ment, Hemab is aim­ing for he­mo­phil­ia to be its first tar­get with re­lat­ed blood dis­eases to fol­low af­ter­ward.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER